Abstract:Zolbetuximab showed survival benefit in a recent phase III trial for claudin 18.2-positive advanced gastric cancer. In our single cohort study claudin 18.2-positive was identified in 24% with almost equal distribution in molecular subtypes. Claudin 18.2-positive had no impact on treatment outcomes with chemotherapy or checkpoint inhibition. Claudin 18.2-positive also had no impact on overall survival in advanced gastric cancer. We conducted comprehensive clinical and molecular characterization of claudin 18.2 expression (CLDN18.2) in advanced gastric or gastroesophageal junction cancer (GC/GEJC). Patients with advanced GC/GEJC who received systemic chemotherapy from October 2015 to December 2019 with available tumor specimens were analyzed. We evaluated clinicopathological features of CLDN18.2 expression with four molecular subtypes: mismatch repair deficient, Epstein–Barr virus-positive, human epidermal growth factor receptor 2-positive, and others. In addition, programmed death-ligand 1 (PD-L1) combined positive score (CPS), genomic alterations, and the expression of immune cell markers were assessed. Clinical outcomes of standard first- or second-line chemotherapy and subsequent anti-programmed cell death protein 1 (anti-PD-1) therapy were also investigated according to CLDN18.2 expression. Among 408 patients, CLDN18.2-positive (moderate-to-strong expression in ≥75%) was identified in 98 patients (24.0%) with almost equal distribution in the four molecular subtypes or CPS subgroups. CLDN18.2-positive was associated with Borrmann type 4, KRAS amplification, low CD16, and high CD68 expression. Overall survival with first-line chemotherapy was not significantly different between CLDN18.2-positive and -negative groups [median 18.4 versus 20.1 months; hazard ratio 1.26 (95% confidence interval 0.89-1.78); P = 0.191] regardless of stratification by PD-L1 CPS ≥5. Progression-free survival and objective response rates of first- and second-line chemotherapy, and anti-PD-1 therapy also showed no significant differences according to CLDN18.2 status. CLDN18.2 expression in advanced GC/GEJC was associated with some clinical and molecular features but had no impact on treatment outcomes with chemotherapy or checkpoint inhibition. CLDN18.2-positive also had no impact on overall survival. This information could be useful to interpret the results from currently ongoing clinical trials of CLDN18.2-targeted therapies for advanced GC/GEJC and to consider a treatment strategy for CLDN18.2-positive GC/GEJC.

Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials

Claudin 18.2 as a novel therapeutic target

Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

Antibody-mediated targeting of Claudins in cancer

Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer

Dichotomous roles of claudins as tumor promoters or suppressors: lessons from knockout mice

A Current and Future Therapeutic Target

Claudins: from gatekeepers of epithelial integrity to potential targets in hepato-pancreato-biliary cancers

Targeting Claudins in Cancer: Diagnosis, Prognosis and Therapy.

The role and mechanism of claudins in cancer

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

Claudin18.2 in Advanced Gastric Cancer

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

Claudins and Gastric Cancer: An Overview

Claudin-18.2 Testing And Its Impact In The Therapeutic Management Of Patients With Gastric And Gastroesophageal Adenocarcinomas: A Literature Review With Expert Opinion

Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies

Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications

Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach